Welcome to our dedicated page for NewGenIvf Group SEC filings (Ticker: NIVFW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on NewGenIvf Group's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into NewGenIvf Group's regulatory disclosures and financial reporting.
NewGenIVF Group Limited announced a major capitalization milestone tied to its strategic pivot toward artificial intelligence and digital assets. The company issued 3,666,667 new shares, bringing total outstanding shares to 10,073,535 after transactions linked to acquiring a 10% equity interest in K25.ai.
NewGenIVF reports a market capitalization of US$7,631,710 as of June 18, 2026, compared with an approximate net asset value of US$25.98 million as of December 31, 2025. Management highlights this gap while noting a US$10 million investment in K25.ai and a digital assets treasury strategy as part of a broader shift toward AI, digital engagement, and prediction markets in APAC.
The company believes this capitalization supports strategic investments, commercial partnerships, and helps it be well-positioned to meet Nasdaq’s proposed US$5 million Market Value of Listed Securities threshold, reinforcing confidence in maintaining its listing as it pursues growth initiatives.
NewGenIVF Group Limited announced a major capitalization milestone tied to its strategic pivot toward artificial intelligence and digital assets. The company issued 3,666,667 new shares, bringing total outstanding shares to 10,073,535 after transactions linked to acquiring a 10% equity interest in K25.ai.
NewGenIVF reports a market capitalization of US$7,631,710 as of June 18, 2026, compared with an approximate net asset value of US$25.98 million as of December 31, 2025. Management highlights this gap while noting a US$10 million investment in K25.ai and a digital assets treasury strategy as part of a broader shift toward AI, digital engagement, and prediction markets in APAC.
The company believes this capitalization supports strategic investments, commercial partnerships, and helps it be well-positioned to meet Nasdaq’s proposed US$5 million Market Value of Listed Securities threshold, reinforcing confidence in maintaining its listing as it pursues growth initiatives.
NewGenIVF Group Limited has agreed to an additional US$4 million investment in K25.ai, acquiring a further 4% equity stake in PredicXion Group Limited. The consideration includes US$1.9 million in cash or digital assets and 1,500,000 newly issued Class A ordinary shares, with a US$100,000 cash deposit paid at signing and the remaining cash due on or before September 30, 2026. Once this deal and prior investments close, NewGenIVF expects to own 10% of K25.ai, implying a US$100 million valuation based on the completed US$10 million Pre-A round. The share portion will be issued as restricted securities under Section 4(a)(2) and/or Regulation S exemptions from U.S. registration.
NewGenIVF Group Limited has agreed to an additional US$4 million investment in K25.ai, acquiring a further 4% equity stake in PredicXion Group Limited. The consideration includes US$1.9 million in cash or digital assets and 1,500,000 newly issued Class A ordinary shares, with a US$100,000 cash deposit paid at signing and the remaining cash due on or before September 30, 2026. Once this deal and prior investments close, NewGenIVF expects to own 10% of K25.ai, implying a US$100 million valuation based on the completed US$10 million Pre-A round. The share portion will be issued as restricted securities under Section 4(a)(2) and/or Regulation S exemptions from U.S. registration.
NewGenIVF Group Limited has entered into a Repurchase and Forbearance Agreement with a significant investor to buy back all outstanding convertible notes and warrants previously issued to that investor. In return, the investor agrees to forbear from converting the notes, exercising the warrants, or completing additional closings under earlier purchase agreements, as long as NewGen remains in compliance.
The repurchased notes and warrants will be cancelled once the agreed purchase prices are fully paid under an installment schedule extending through late 2027, which the company can prepay without penalty. NewGen expects this to remove a major source of potential equity dilution, simplify its capital structure, and improve clarity for shareholders as it pursues strategic initiatives, including digital asset treasury plans and potential expansion of its stake in K25.ai.
NewGenIVF Group Limited has entered into a Repurchase and Forbearance Agreement with a significant investor to buy back all outstanding convertible notes and warrants previously issued to that investor. In return, the investor agrees to forbear from converting the notes, exercising the warrants, or completing additional closings under earlier purchase agreements, as long as NewGen remains in compliance.
The repurchased notes and warrants will be cancelled once the agreed purchase prices are fully paid under an installment schedule extending through late 2027, which the company can prepay without penalty. NewGen expects this to remove a major source of potential equity dilution, simplify its capital structure, and improve clarity for shareholders as it pursues strategic initiatives, including digital asset treasury plans and potential expansion of its stake in K25.ai.
NewGenIvf Group Ltd filed an amended initial insider ownership report (Form 3/A) for Chief Financial Officer Chung Ho Fai. This amendment lists no insider transactions, exercises, gifts, tax withholdings, restructurings, or derivative positions in the data provided.
NewGenIvf Group Ltd filed an amended initial insider ownership report (Form 3/A) for Chief Financial Officer Chung Ho Fai. This amendment lists no insider transactions, exercises, gifts, tax withholdings, restructurings, or derivative positions in the data provided.
NewGenIvf Group Limited has expanded its Board by appointing four new independent directors. Ms. Lee Sze Mun joined as an independent director effective June 1, 2026, bringing over 22 years of experience in financial accounting, taxation, and group consolidation.
Mr. Lau Tsz Hin Vincent, Mr. Lam Chun Tung Patrick, and Mr. Cheung Kong Yiu were each appointed as independent directors effective June 8, 2026. The new directors contribute backgrounds in finance, risk management, digital assets, quantitative trading, and technology entrepreneurship, broadening the Board’s mix of skills and industry experience.
NewGenIvf Group Limited has expanded its Board by appointing four new independent directors. Ms. Lee Sze Mun joined as an independent director effective June 1, 2026, bringing over 22 years of experience in financial accounting, taxation, and group consolidation.
Mr. Lau Tsz Hin Vincent, Mr. Lam Chun Tung Patrick, and Mr. Cheung Kong Yiu were each appointed as independent directors effective June 8, 2026. The new directors contribute backgrounds in finance, risk management, digital assets, quantitative trading, and technology entrepreneurship, broadening the Board’s mix of skills and industry experience.
HRT FINANCIAL LP, a ten percent owner of NewGenIvf Group Ltd, reported an open-market sale of Common Stock. On June 4, 2026, it sold 64,945 shares at $0.781 per share. After this transaction, HRT FINANCIAL LP directly holds 18,134 shares of NewGenIvf common stock.
HRT FINANCIAL LP, a ten percent owner of NewGenIvf Group Ltd, reported an open-market sale of Common Stock. On June 4, 2026, it sold 64,945 shares at $0.781 per share. After this transaction, HRT FINANCIAL LP directly holds 18,134 shares of NewGenIvf common stock.
NewGenIvf Group Ltd insiders Wing Fung Alfred Siu and Hei Yue Tina Fong filed Amendment No. 1 to update their Schedule 13D on the company’s Class B ordinary shares. As of June 4, 2026, they beneficially own 113,771 Class B shares, representing 2.8% of that class.
On May 4, 2026, each was granted options to acquire 56,851 Class B shares under the 2024 Share Incentive Plan. They exercised all 56,851 options each on June 4, 2026 at an exercise price of US$0.0001 per share, and the company issued fully paid Class B shares to them. They state that they hold these shares to retain control and have amended their Joint Filing Agreement to continue reporting jointly.
NewGenIvf Group Ltd insiders Wing Fung Alfred Siu and Hei Yue Tina Fong filed Amendment No. 1 to update their Schedule 13D on the company’s Class B ordinary shares. As of June 4, 2026, they beneficially own 113,771 Class B shares, representing 2.8% of that class.
On May 4, 2026, each was granted options to acquire 56,851 Class B shares under the 2024 Share Incentive Plan. They exercised all 56,851 options each on June 4, 2026 at an exercise price of US$0.0001 per share, and the company issued fully paid Class B shares to them. They state that they hold these shares to retain control and have amended their Joint Filing Agreement to continue reporting jointly.
NewGenIvf Group director Siu Wing Fung Alfred exercised vested stock options to acquire 56,851 Class B Ordinary Shares at $0.0001 per share on June 4, 2026. The exercise, under the 2024 Share Incentive Plan and an employee option agreement, raised his direct holdings to 56,881 shares after the transaction.
NewGenIvf Group director Siu Wing Fung Alfred exercised vested stock options to acquire 56,851 Class B Ordinary Shares at $0.0001 per share on June 4, 2026. The exercise, under the 2024 Share Incentive Plan and an employee option agreement, raised his direct holdings to 56,881 shares after the transaction.
NewGenIvf Group Ltd director Fong Hei Yue Tina exercised stock options to acquire additional shares in the company. She exercised vested options to receive 56,851 Class B Ordinary Shares at an exercise price of $0.0001 per share under the issuer's 2024 Share Incentive Plan.
Following this option exercise, she directly holds 56,890 Class B Ordinary Shares. The options were granted under an employee share option agreement dated 4 May 2026, were accelerated by the independent directors on 26 May 2026, and were exercised on 4 June 2026. This is a compensation-related derivative exercise, not an open-market purchase or sale.
NewGenIvf Group Ltd director Fong Hei Yue Tina exercised stock options to acquire additional shares in the company. She exercised vested options to receive 56,851 Class B Ordinary Shares at an exercise price of $0.0001 per share under the issuer's 2024 Share Incentive Plan.
Following this option exercise, she directly holds 56,890 Class B Ordinary Shares. The options were granted under an employee share option agreement dated 4 May 2026, were accelerated by the independent directors on 26 May 2026, and were exercised on 4 June 2026. This is a compensation-related derivative exercise, not an open-market purchase or sale.
HRT Financial LP, a ten percent owner of NewGenIvf Group Ltd, reported open-market purchases of the company’s Common Stock. On June 2, it bought 23,018 shares at an average price of $0.944 per share. On June 3, it bought an additional 11,738 shares at an average price of $0.875 per share. After these transactions, HRT Financial LP directly holds 83,079 shares of NewGenIvf common stock.
HRT Financial LP, a ten percent owner of NewGenIvf Group Ltd, reported open-market purchases of the company’s Common Stock. On June 2, it bought 23,018 shares at an average price of $0.944 per share. On June 3, it bought an additional 11,738 shares at an average price of $0.875 per share. After these transactions, HRT Financial LP directly holds 83,079 shares of NewGenIvf common stock.